Zacks: Brokerages Anticipate ADMA Biologics Inc (NASDAQ:ADMA) Will Announce Quarterly Sales of $3.52 Million
Analysts expect ADMA Biologics Inc (NASDAQ:ADMA) to report sales of $3.52 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for ADMA Biologics’ earnings, with the highest sales estimate coming in at $3.94 million and the lowest estimate coming in at $3.10 million. ADMA Biologics reported sales of $2.27 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 55.1%. The firm is expected to report its next quarterly earnings report on Friday, August 11th.
According to Zacks, analysts expect that ADMA Biologics will report full year sales of $3.52 million for the current fiscal year, with estimates ranging from $19.75 million to $20.10 million. For the next financial year, analysts expect that the company will post sales of $38.71 million per share, with estimates ranging from $28.32 million to $49.10 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that cover ADMA Biologics.
ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Friday, May 12th. The biotechnology company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by $0.23. The business had revenue of $2.63 million during the quarter, compared to the consensus estimate of $3.35 million.
ADMA has been the topic of a number of analyst reports. Maxim Group set a $13.00 target price on shares of ADMA Biologics and gave the stock a “buy” rating in a research report on Monday, May 15th. ValuEngine lowered shares of ADMA Biologics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd.
Shares of ADMA Biologics (NASDAQ ADMA) opened at 3.64 on Wednesday. The firm’s 50-day moving average price is $3.47 and its 200-day moving average price is $4.36. ADMA Biologics has a 12-month low of $2.93 and a 12-month high of $8.00. The firm’s market capitalization is $46.91 million.
ADMA Biologics Company Profile
ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.